New York Life Investment Management LLC Purchases 186 Shares of The Clorox Company (NYSE:CLX)

New York Life Investment Management LLC boosted its position in The Clorox Company (NYSE:CLX) by 0.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,969 shares of the company’s stock after acquiring an additional 186 shares during the quarter. New York Life Investment Management LLC’s holdings in Clorox were worth $2,847,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CLX. Qube Research & Technologies Ltd increased its stake in shares of Clorox by 75.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,130,481 shares of the company’s stock valued at $148,161,000 after purchasing an additional 487,974 shares during the last quarter. International Assets Investment Management LLC grew its position in Clorox by 17,658.5% in the fourth quarter. International Assets Investment Management LLC now owns 484,453 shares of the company’s stock valued at $69,078,000 after acquiring an additional 481,725 shares during the last quarter. Acadian Asset Management LLC raised its stake in Clorox by 39.6% during the third quarter. Acadian Asset Management LLC now owns 1,467,713 shares of the company’s stock worth $192,319,000 after acquiring an additional 415,999 shares in the last quarter. FMR LLC lifted its holdings in shares of Clorox by 17.4% in the third quarter. FMR LLC now owns 2,415,054 shares of the company’s stock worth $316,517,000 after acquiring an additional 357,964 shares during the last quarter. Finally, Nuance Investments LLC boosted its stake in shares of Clorox by 25.7% in the 3rd quarter. Nuance Investments LLC now owns 1,325,789 shares of the company’s stock valued at $173,758,000 after purchasing an additional 271,133 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Price Performance

Shares of NYSE CLX opened at $138.23 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.90 and a debt-to-equity ratio of 9.73. The company has a market capitalization of $17.17 billion, a PE ratio of 71.62, a P/E/G ratio of 2.16 and a beta of 0.44. The firm has a fifty day simple moving average of $148.45 and a 200 day simple moving average of $143.43. The Clorox Company has a twelve month low of $114.68 and a twelve month high of $176.24.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.38. Clorox had a return on equity of 302.49% and a net margin of 3.33%. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the business earned $1.51 EPS. The firm’s revenue was down 5.3% compared to the same quarter last year. On average, sell-side analysts forecast that The Clorox Company will post 5.83 EPS for the current year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Wednesday, April 24th will be given a dividend of $1.20 per share. This represents a $4.80 annualized dividend and a dividend yield of 3.47%. The ex-dividend date is Tuesday, April 23rd. Clorox’s dividend payout ratio (DPR) is 248.71%.

Wall Street Analyst Weigh In

CLX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. cut their target price on shares of Clorox from $159.00 to $158.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. The Goldman Sachs Group started coverage on Clorox in a report on Friday, March 1st. They issued a “sell” rating and a $140.00 target price for the company. UBS Group cut their price target on Clorox from $164.00 to $159.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Evercore ISI reduced their price target on Clorox from $145.00 to $142.00 and set an “underperform” rating on the stock in a report on Wednesday, May 1st. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Clorox from $155.00 to $151.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. Four analysts have rated the stock with a sell rating and thirteen have issued a hold rating to the company’s stock. According to data from MarketBeat.com, Clorox presently has an average rating of “Hold” and an average target price of $146.43.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.